Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 8 November 2024, 20:23 HKT/SGT
Share:
ITC's Final Decision Confirms Innoscience's Customers Remain Unaffected by the Innoscience-EPC Patent Row
- Finds No Infringement of the '508 Patent
- and Paves the Way for Designing Around the Remaining '294 Patent Currently Stands Challenged as Invalid at USPTO

HONG KONG, Nov 8, 2024 - (ACN Newswire) - Innoscience Technology, a company founded to create a global energy ecosystem based on high-performance, low-cost, gallium-nitride-on-silicon (GaN-on-Si) power solutions, announced today that the U.S. International Trade Commission’s (“ITC”) November 7, 2024 final determination has confirmed the ability of Innoscience’s customers to import their products into U.S. remain unaffected by the ongoing patent dispute between Innoscience and Efficient Power Conversion Corporation (“EPC”).

In May last year, EPC launched a lawsuit against Innoscience at the ITC, falsely alleging infringement of EPC’s ’508 and ’294 patents. Following an administrative law judge’s initial determination in the past July finding no infringement of claim 1 (the only asserted claim) of the ’508 patent, the latest ITC final determination once again affirmed no violation as to this patent—a huge success for Innoscience.

The final determination, however, affirmed the part of the judge’s initial determination that found violation as to claims 2 and 3 the ’294 patent. The ITC hence has determined to issue a limited exclusion order prohibiting importation of certain accused Innoscience chips. Innoscience disagrees with and will appeal this ruling. This is at least because the ‘294 patent is invalid. Indeed, the U.S Patent and Trademark Office (“USPTO”) instituted an inter partes review (“IPR”) challenging all claims of the ’294 patent under four different grounds and has agreed with Innoscience’s invalidity arguments. The ’294 IPR decision will issue in March 2025.

Innoscience also notes it is established U.S. law that the limited exclusion order does not prohibit Innoscience’s customers from importing end products that use the accused chips. Moreover, since the final decision clarified the meaning of the claim term “compensated GaN layer,” which is at the center of the dispute surrounding the ’294 patent, it has provided clear guidance for Innoscience to design around the ’294 patent by avoiding use of the “compensated GaN layer.” Innoscience already has the design around in place and will release the new products soon.  

Accordingly, the EPC litigation shall have no impact on Innoscience’s customers. Moreover, Innoscience will continue to solve the dispute with EPC through appeals in court and invalidity challenges at the USPTO, and is confident that it will achieve a final complete victory. 




Topic: Press release summary Sectors: Electronics
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
iHerb Expands Consumer Benefits Across Asia with 618 Shopping Festival  
June 7, 2026 14:30 HKT/SGT
Central Asia visit drives multi-sector collaboration, Business delegation signed 66 MoUs and agreements to seize Belt and Road opportunities  
June 6, 2026 21:50 HKT/SGT
Alltronics Officially Opens Malaysia Facility  
June 5, 2026 12:14 HKT/SGT
ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801's Renoprotective Potential in Oral Presentation  
June 5, 2026 11:01 HKT/SGT
ONERHT Foundation Raises Over S$280,000 for Local Charities and Announces New Leadership at 11th Anniversary Charity Golf & Gala Dinner  
Friday, June 5, 2026 10:00:00 AM
Operations Started for the Nagaoka Methanation Demonstration Utilizing the CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates
  
Thursday, June 4, 2026 10:49:00 PM
Fujitsu and Daiichi Life Group Launch Joint Research to Advance Asset Management with Quantum Technology  
Thursday, June 4, 2026 10:17:00 PM
"Making Children and Adults Smile:" Honda Launches the SMILE RIDER PROJECT  
Thursday, June 4, 2026 9:46:00 PM
GR Premiers GRMN Corolla  
Thursday, June 4, 2026 9:05:00 PM
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market  
June 4, 2026 20:43 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: